司帕沙星衍生物(YH37)体外抗微生物活性研究(英文)  

In vitro antimicrobial activity of sparfloxacin derivative (YH37)

作　　者：王兆慧[1] 叶辉[1] 杨玉社[2] 武济民[2] 陈凯先[2] 嵇汝运[2] 

机构地区：[1]江苏南通大学生命科学学院,南通226007 [2]中国科学院上海生命科学研究院上海药物研究所,上海201203

出　　处：《中国抗生素杂志》2008年第2期93-96,共4页Chinese Journal of Antibiotics

基　　金：国家自然科学基金(№29672037)资助项目

摘　　要：采用微量稀释法测定了5-氨基-1-环丙基-6,8-二氟-1,4-二氢-7-(3-甲基-1-哌嗪基)-4-氧代喹啉-6-羧酸(YH37)对临床分离的人型支原体(Mh)、解脲脲原体(Uu)以及细菌标准菌株的体外敏感性。结果显示,YH37对Mh的抑制活性较强,MIC90为0.25mg/L,是司帕沙星的1/8;对Uu的MIC90为1mg/L,是司帕沙星的1/4。YH37对Mh、Uu的喹诺酮耐药株有一定的抑制活性,其MIC分别为CPLX的1/4～1/16。YH37对被测细菌的抑制活性是左氧氟沙星的1/8～1/16,是司帕沙星的1/2。The susceptibilities of mycoplasma and bacteria to the derivative （YH37） of sparfloxacin was determined by microdilution method in vitro. Results showed YH37 against Mycoplasma hominis（Mh） （0.25mg/L）, and that the minimum inhibition concentration （MICgo） of Ureaplasma urealyticum（Uu） （1.0mg/L）, were 1/8 those of sparfloxacin against Mh, and 1/4 those of sparfloxacin against Uu. YH37 was still highly susceptibility to quinolone-resistant strains of Mh and Uu. Its MICs were 1/4 ～1/16 of that of ciprofloxacin, respectively. MICs of YH37 for bacteria were 1/8～ 1/16 of that of levofloxacin and 1/2 of that of sparfloxacin.

关 键 词：抗支原体活性 抗细菌活性 最低抑制浓度 司帕沙星 衍生物 YH37 

分 类 号：R969[医药卫生—药理学]